Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader access to Bristol Myers Squibb’s CAR T-cell therapies Breyanzi and Abecma ...

"FDA approves label expansion of AbbVie hepatitis C therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

The FDA has approved required updates to the labeling of Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines to include revised warnings about the risk of myocarditis and pericarditis ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed ...

Company News Published 06/26/2025, 09:37 AM 0 FDA approves label changes for Emmaus’ sickle cell treatment EMMA 8.65% ...

Melbourne-headquartered Telix Pharmaceuticals Limited, a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated ...

FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.

TORRANCE, Calif. - Emmaus Life Sciences, Inc. (OTCQB:EMMA), a biopharmaceutical company maintaining impressive gross profit margins of 93%, announced Thursday that the U.S. Food and Drug ...

FDA approves twice-a-year HIV prevention drug that could help end the virus worldwide It reduces transmissions by up to 96%, but now world governments and big-dollar funders will need to step in.